CareDx Q1 Earnings Exceed Expectations with Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Should l Buy CDNA?
Source: seekingalpha
- Earnings Beat: CareDx reported a Q1 non-GAAP EPS of $0.34, surpassing expectations by $0.21, indicating a significant improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $117.7 million, a 39.5% year-over-year increase, exceeding market expectations by $13.25 million, demonstrating sustained competitive strength in the market.
- 2026 Revenue Guidance Raised: CareDx raised its 2026 revenue guidance to between $447 million and $465 million, surpassing the consensus estimate of $437.43 million, reflecting a positive outlook for future growth.
- Positive Stock Reaction: Following the strong earnings report, CareDx shares rose by 13%, indicating market confidence in the company's future prospects and positive investor sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDNA
Wall Street analysts forecast CDNA stock price to fall
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 21.820
Low
18.00
Averages
18.00
High
18.00
Current: 21.820
Low
18.00
Averages
18.00
High
18.00
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CareDx Q1 Earnings Exceed Expectations with Revenue Growth
- Earnings Beat: CareDx reported a Q1 non-GAAP EPS of $0.34, surpassing expectations by $0.21, indicating a significant improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $117.7 million, a 39.5% year-over-year increase, exceeding market expectations by $13.25 million, demonstrating sustained competitive strength in the market.
- 2026 Revenue Guidance Raised: CareDx raised its 2026 revenue guidance to between $447 million and $465 million, surpassing the consensus estimate of $437.43 million, reflecting a positive outlook for future growth.
- Positive Stock Reaction: Following the strong earnings report, CareDx shares rose by 13%, indicating market confidence in the company's future prospects and positive investor sentiment.
See More
CareDx Reports Q2 2025 Financial Results with Strong Growth Indicators
- Financial Performance Growth: CareDx reported adjusted revenue of $90.5 million for Q2 2025, reflecting a 14% year-over-year increase, indicating strong market performance and a projected annual revenue range of $367 million to $373 million, showcasing sustained market demand and effective company strategy.
- Testing Services Expansion: The company achieved $66 million in Testing Services revenue for the second quarter, up 14% year-over-year, delivering approximately 49,500 tests, marking the eighth consecutive quarter of testing volume growth, underscoring its market leadership in monitoring heart, kidney, and lung transplants.
- New Product Launch: At the World Transplant Congress, CareDx unveiled AlloSure Plus, an AI-driven diagnostic tool that provides personalized rejection risk scores, expected to be seamlessly reported through EPIC integrations in the second half of the year, enhancing the company's competitive edge in kidney transplant monitoring.
- Policy Impact Assessment: CareDx is actively addressing the new draft LCD policy, estimating a potential $30 million annual revenue headwind if implemented, yet remains committed to driving protocol adoption to improve patient outcomes and maintain market share.
See More
CareDx (CDNA) Q2 2025 Earnings Transcript
See More
CareDx Expected to Exceed Q1 Earnings Estimates
- Earnings Announcement: CareDx is set to announce its Q1 earnings on April 28 after market close, with a consensus EPS estimate of $0.13, reflecting a 44.4% year-over-year increase, indicating significant improvement in profitability that could positively impact stock prices.
- Revenue Growth Expectations: The anticipated Q1 revenue of $104.45 million represents a 23.8% year-over-year growth, showcasing CareDx's strong performance in market demand and product sales, further solidifying its position in the industry.
- Historical Performance Review: Over the past two years, CareDx has beaten EPS and revenue estimates 75% of the time, which enhances investor confidence and may attract more institutional investors to the stock.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw no upward revisions but five downward adjustments, while revenue estimates experienced five upward revisions and two downward, reflecting mixed market sentiments regarding the company's future performance, warranting close attention to the earnings results.
See More
CareDx Launches AlloSeq Nano Genotyping Solution for Transplant Labs
- Innovative Genotyping Technology: CareDx introduced AlloSeq Nano at the 2026 EFI Conference, a nanopore-based HLA and ABO genotyping solution that delivers high-resolution genotyping in under three hours, significantly enhancing efficiency for transplant laboratories.
- Efficient Workflow: The AlloSeq Nano's single-step amplification and prep workflow requires approximately 45 minutes of hands-on time to assay eleven HLA loci plus ABO in a single test, reducing operational complexity and improving accuracy, thereby enhancing laboratory testing capabilities.
- Product Portfolio Expansion: The launch of AlloSeq Nano expands CareDx's transplant lab products portfolio, supporting a broader range of laboratory throughput requirements and strengthening the company's competitive position in the precision medicine sector.
- Business Restructuring Plan: CareDx announced the divestiture of its Lab Products business to EuroBio Scientific, expected to close by the end of Q3 2026, allowing the company to focus on its core precision medicine solutions and optimize resource allocation for future growth.
See More
Major U.S. Indices Hit All-Time Highs Amid Positive Market Sentiment
- CareDx Divestiture: CareDx announced the divestment of its Lab Products business to EuroBio Scientific for $170 million in cash, leading to an over 8% surge in after-hours trading, which will allow the company to focus on precision medicine and enhance its competitive edge in the market.
- J.B. Hunt Earnings Beat: J.B. Hunt Transport Services reported a GAAP EPS of $1.49 for the first quarter, surpassing the $1.46 consensus estimate, while operating revenue rose 5% year-over-year to $3.06 billion, indicating strong performance in the logistics sector.
- SL Green Disappoints: SL Green Realty Corp. posted a first-quarter FFO per share of $0.84, missing the $1.08 consensus estimate, although revenue of $253.1 million exceeded expectations, leading to a 4% decline in after-hours trading as the market expressed concerns about future performance.
- QuidelOrtho Revenue Warning: QuidelOrtho issued preliminary first-quarter revenue guidance with a midpoint of $617.5 million, significantly below the $679.59 million consensus, primarily due to a weaker respiratory season and changes in reimbursement policies in China, resulting in an approximately 11% drop in stock price.
See More
CareDx Q1 Earnings Exceed Expectations with Revenue Growth
- Earnings Beat: CareDx reported a Q1 non-GAAP EPS of $0.34, surpassing expectations by $0.21, indicating a significant improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $117.7 million, a 39.5% year-over-year increase, exceeding market expectations by $13.25 million, demonstrating sustained competitive strength in the market.
- 2026 Revenue Guidance Raised: CareDx raised its 2026 revenue guidance to between $447 million and $465 million, surpassing the consensus estimate of $437.43 million, reflecting a positive outlook for future growth.
- Positive Stock Reaction: Following the strong earnings report, CareDx shares rose by 13%, indicating market confidence in the company's future prospects and positive investor sentiment.
See More
CareDx Reports Q2 2025 Financial Results with Strong Growth Indicators
- Financial Performance Growth: CareDx reported adjusted revenue of $90.5 million for Q2 2025, reflecting a 14% year-over-year increase, indicating strong market performance and a projected annual revenue range of $367 million to $373 million, showcasing sustained market demand and effective company strategy.
- Testing Services Expansion: The company achieved $66 million in Testing Services revenue for the second quarter, up 14% year-over-year, delivering approximately 49,500 tests, marking the eighth consecutive quarter of testing volume growth, underscoring its market leadership in monitoring heart, kidney, and lung transplants.
- New Product Launch: At the World Transplant Congress, CareDx unveiled AlloSure Plus, an AI-driven diagnostic tool that provides personalized rejection risk scores, expected to be seamlessly reported through EPIC integrations in the second half of the year, enhancing the company's competitive edge in kidney transplant monitoring.
- Policy Impact Assessment: CareDx is actively addressing the new draft LCD policy, estimating a potential $30 million annual revenue headwind if implemented, yet remains committed to driving protocol adoption to improve patient outcomes and maintain market share.
See More
CareDx (CDNA) Q2 2025 Earnings Transcript
See More
CareDx Expected to Exceed Q1 Earnings Estimates
- Earnings Announcement: CareDx is set to announce its Q1 earnings on April 28 after market close, with a consensus EPS estimate of $0.13, reflecting a 44.4% year-over-year increase, indicating significant improvement in profitability that could positively impact stock prices.
- Revenue Growth Expectations: The anticipated Q1 revenue of $104.45 million represents a 23.8% year-over-year growth, showcasing CareDx's strong performance in market demand and product sales, further solidifying its position in the industry.
- Historical Performance Review: Over the past two years, CareDx has beaten EPS and revenue estimates 75% of the time, which enhances investor confidence and may attract more institutional investors to the stock.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw no upward revisions but five downward adjustments, while revenue estimates experienced five upward revisions and two downward, reflecting mixed market sentiments regarding the company's future performance, warranting close attention to the earnings results.
See More
CareDx Launches AlloSeq Nano Genotyping Solution for Transplant Labs
- Innovative Genotyping Technology: CareDx introduced AlloSeq Nano at the 2026 EFI Conference, a nanopore-based HLA and ABO genotyping solution that delivers high-resolution genotyping in under three hours, significantly enhancing efficiency for transplant laboratories.
- Efficient Workflow: The AlloSeq Nano's single-step amplification and prep workflow requires approximately 45 minutes of hands-on time to assay eleven HLA loci plus ABO in a single test, reducing operational complexity and improving accuracy, thereby enhancing laboratory testing capabilities.
- Product Portfolio Expansion: The launch of AlloSeq Nano expands CareDx's transplant lab products portfolio, supporting a broader range of laboratory throughput requirements and strengthening the company's competitive position in the precision medicine sector.
- Business Restructuring Plan: CareDx announced the divestiture of its Lab Products business to EuroBio Scientific, expected to close by the end of Q3 2026, allowing the company to focus on its core precision medicine solutions and optimize resource allocation for future growth.
See More
Major U.S. Indices Hit All-Time Highs Amid Positive Market Sentiment
- CareDx Divestiture: CareDx announced the divestment of its Lab Products business to EuroBio Scientific for $170 million in cash, leading to an over 8% surge in after-hours trading, which will allow the company to focus on precision medicine and enhance its competitive edge in the market.
- J.B. Hunt Earnings Beat: J.B. Hunt Transport Services reported a GAAP EPS of $1.49 for the first quarter, surpassing the $1.46 consensus estimate, while operating revenue rose 5% year-over-year to $3.06 billion, indicating strong performance in the logistics sector.
- SL Green Disappoints: SL Green Realty Corp. posted a first-quarter FFO per share of $0.84, missing the $1.08 consensus estimate, although revenue of $253.1 million exceeded expectations, leading to a 4% decline in after-hours trading as the market expressed concerns about future performance.
- QuidelOrtho Revenue Warning: QuidelOrtho issued preliminary first-quarter revenue guidance with a midpoint of $617.5 million, significantly below the $679.59 million consensus, primarily due to a weaker respiratory season and changes in reimbursement policies in China, resulting in an approximately 11% drop in stock price.
See More
